

## Hikma to host meet the management and site visit in Columbus, Ohio

**London, 17 March 2025** – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, will host sell-side analysts and investors at its Columbus, Ohio manufacturing and R&D facility on Thursday 15 May 2025.

Our state-of-the-art 1,000,000 sq. ft. facility produces oral, respiratory and other generic and specialty products for our Generics business and our CMO partners. It is one of Hikma's four US manufacturing facilities producing a broad range of medicines for US patients and healthcare providers.

Alongside a tour of the facility, Hafrun Fridriksdottir, President of Generics and Dr Bill Larkins, President of Injectables will present on our Generics and Injectables businesses, updating on strategy and our positioning for long-term, sustainable growth.

Materials and a recording of the presentations and Q&A will be made available on our website following the event.

If you would like to attend in person, please email [djadeja@hikma.com](mailto:djadeja@hikma.com).

– ENDS –

### Enquiries:

#### Hikma (Investors)

Susan Ringdal EVP, Strategic Planning and Global Affairs	+44 (0)20 7399 2760/ +44 7776 477050
Guy Featherstone Director, Investor Relations	+44 (0)20 3892 4389/ +44 7795 896738
Layan Kalisse Senior Associate, Investor Relations	+44 (0)20 7399 2788/ +44 7970 709912

### About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: [www.hikma.com](http://www.hikma.com)